Sigrid Deller

A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec

Stefan Korsatko, Sigrid Deller, Gerd Koehler et al. · Clinical Drug Investigation · 2013 · 89 citations

Pharmaceutical Science, Medicine, Pharmacodynamic Profiles +8

Steady state is reached within 2–3 days of once‐daily administration of degludec, a basal insulin with an ultralong duration of action

Tim Heise, Stefan Korsatko, Leszek Nosek et al. · Journal of Diabetes · 2015 · 44 citations

Counter‐regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo‐controlled, double‐blind, crossover trial

Thomas R. Pieber, Sigrid Deller, Stefan Korsatko et al. · Diabetes Obesity and Metabolism · 2015 · 43 citations

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus

Stefan Korsatko, Sigrid Deller, Julia K. Mader et al. · Drugs & Aging · 2013 · 36 citations · Full text

Enhanced Absorption of Insulin Aspart as the Result of a Dispersed Injection Strategy Tested in a Randomized Trial in Type 1 Diabetic Patients

Julia K. Mader, Thomas Birngruber, Stefan Korsatko et al. · Diabetes Care · 2012 · 25 citations · Full text